1. Tirofiban Meta-Analysis

2. Tirofiban Meta-Analysis: Efficacy at 30 Days
Administration Pre-Angiography (Upstream) and PCI Likely (Downstream)
P<.00001
% of Patients
P=.001
*12 g/kg bolus over 30 min (upstream) and 10 g/kg bolus & 25 g/kg bolus (downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

3. Tirofiban Meta-Analysis: Death or MI at 30 Days
Administration Pre-Angiography (Upstream) and PCI Likely (Downstream)
P=.002
% of Patients
P=.006
P=.07 m m m
*Bolus over 30 Minutes (Upstream)
During PCI (Downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

4. Tirofiban Meta-Analysis: Mortality at 30 Days
Administration Pre-Angiography (Upstream) and PCI Likely (Downstream)
P=.01
% of Patients
P=.07
P=.25 m m m
*Bolus over 30 Minutes (Upstream)
During PCI (Downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

5. Tirofiban Meta-Analysis: Safety at 30 Days
Administration Pre-Angiography (Upstream) and PCI Likely (Downstream)
P=.002
% of Patients
P=.24
*12 g/kg bolus over 30 min (upstream) and 10 g/kg bolus & 25 g/kg bolus (downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

6. Tirofiban Meta-Analysis: Efficacy at 30 Days
Administration when PCI Likely or Planned (Downstream)
P=.11
% of Patients
P=.70
*10 g/kg bolus & 25 g/kg bolus (downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

7. Tirofiban Meta-Analysis: Death or MI at 30 Days
Administration when PCI Likely or Planned (Downstream)
P=.03
P=.54
% of Patients m m
*10 g/kg bolus & 25 g/kg bolus (downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

8. Tirofiban Meta-Analysis: Mortality at 30 Days
Administration when PCI Likely or Planned (Downstream)
P=.38
% of Patients
P=.65 m m
*10 g/kg bolus & 25 g/kg bolus (downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

9. Tirofiban Meta-Analysis: Safety at 30 Days
Administration when PCI Likely or Planned (Downstream)
P<.001
% of Patients
P=.04
*10 g/kg bolus & 25 g/kg bolus (downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

10. Tirofiban Meta-Analysis: Death or MI at Long-Term Follow Up
Administration when PCI Likely or Planned (Downstream)
P=.34
P=.10
% of Patients
P=.35 m m
*10 g/kg bolus & 25 g/kg bolus (downstream)
Valgimigli M, et al. EHJ. Published online September 14, 2009.

11. Tirofiban Meta-Analysis: Key Points
Tirofiban when compared with placebo or bivalirudin at 30 days
Significantly reduced mortality and the composite of death or MI
12 mg/kg Bolus (label) administered over 30 minutes (Upstream)
Significantly reduced mortality and the composite of death or MI
25 mg/kg Bolus (Downstream)
Significantly reduced the composite of death or MI
Significantly increased TIMI minor bleeding and thrombocytopenia
Demonstrated no significant difference in TIMI major bleeding

12. Tirofiban Meta-Analysis: Key Points
Tirofiban when compared with abciximab (Downstream only)
Demonstrated no significant difference in mortality and the composite of death or MI at 30 days or long-term follow up
10 mg/kg Bolus – TARGET Trial (Downstream)
Demonstrated a significant increase in the composite of death or MI at 30 days, which was lost at long-term follow up
Demonstrated no significant difference in mortality at 30 days or at long-term follow up
25 mg/kg Bolus (Downstream)
Demonstrated no significant difference in mortality or the composite of death or MI at 30 days or at long-term follow up
Significantly reduced TIMI minor bleeding and thrombocytopenia
Demonstrated no significant difference in TIMI major bleeding